Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that the new drug EndoTAG-1 will improve tumor volume reduction as
measured by Magnetic Resonance Imaging when added to a standard chemotherapy regimen of
weekly paclitaxel. This is a prospective single-center study that will investigate the
activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative breast
cancer that are candidate for receiving chemotherapy before surgery (neoadjuvant
chemotherapy).